ARRB1-promoted NOTCH1 degradation is suppressed by oncomiR miR-223 in T cell acute lymphoblastic leukemia.
T cell acute lymphoblastic leukemia (T-ALL) is a type of aggressive leukemia with inferior prognosis. While activating mutations of NOTCH1 are observed in most T-ALL cases, these mutations alone are not sufficient to drive the full development of T-ALL. β-Arrestins (ARRBs) are versatile and multifunctional adapter proteins that regulate diverse cellular functions, including promoting the development of cancer. However, the role of ARRBs in T-ALL have largely remained elusive. In this study, we showed that ARRB1 is expressed at low levels in assayed T-ALL clinical samples and cell lines. Exogenous ARRB1 expression inhibited T-ALL proliferation and improved the survival of T-ALL xenograft animals. ARRB1 facilitated NOTCH1 ubiquitination and degradation through interactions with NOTCH1 and DTX1. Mechanistically, the oncogenic microRNA (oncomiR) miR-223 targeted the 3'-UTR of ARRB1 (BUTR) and inhibited its expression in T-ALL. Furthermore, overexpression of the ARRB1-derived miR-223 sponge BUTR suppressed T-ALL cell proliferation and induced apoptosis. Collectively, these results demonstrate that ARRB1 acts as a tumor suppressor in T-ALL by promoting NOTCH1 degradation, which is inhibited by elevated miR-223, suggesting that ARRB1 may serve as a valid drug target in the development of novel T-ALL therapeutics.